Arcoma

Arcoma Financing Cash Flow

The Net Financing Cash Flow of Arcoma (ARCOMA.ST) as of Oct 30, 2026 is 10.36 M SEK. In the previous year, Net Financing Cash Flow was -3.87 M SEK — a change of -367.48% (higher).

Financing Cash Flow

10.36 MSEK

YoY

-367.48%

Last updated:

Net Financing Cash Flow of Arcoma is 2025 10.36 M SEK. Net Financing Cash Flow of Arcoma was 2024 -3.87 M SEK. It decreases by -367.48% higher compared to the previous year.

The Arcoma Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
4.26 M SEK
Jan 1, 2019
-6.08 M SEK
Jan 1, 2020
11.23 M SEK
Jan 1, 2021
2.40 M SEK
Jan 1, 2022
9.65 M SEK
Jan 1, 2023
-21.22 M SEK
Jan 1, 2024
-3.87 M SEK
Jan 1, 2025
10.36 M SEK
The Arcoma Financing Cash Flow history
YEARFinancing Cash FlowYoY
10.36 MSEK-367.48%
-3.87 MSEK-81.74%
-21.22 MSEK-319.98%
9.65 MSEK+302.76%
2.40 MSEK-78.68%
11.23 MSEK-284.86%
-6.08 MSEK-242.65%
4.26 MSEK+46.14%
2.92 MSEK-7.78%
3.16 MSEK-81.09%
16.71 MSEK+231.32%
5.04 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Net Financing Cash Flow of Arcoma is 10.36 M SEK in 2025.

Net Financing Cash Flow of Arcoma changed from -3.87 M SEK to 10.36 M SEK, representing a -367.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Arcoma since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Arcoma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Arcoma

All Key Metrics — Arcoma